Advertisement: Simpsons Creative
Advertisement: EBCam mid banner
Advertisement: Mogrify
Advertisement: TTP
Advertisement: Cambridge Network
ARM Innovation Hub
Advertisement EY mid banner
Mid banner advertisement: BDO
RealVNC mid banner careers
Barr Ellison Solicitors – commercial property
RealVNC mid-banner general
Advertisement: RSM
Advertisement: Wild Knight Vodka
9 March, 2014 - 18:41 By News Desk

Transatlantic alliance changes game on drug trials

Derek Hill

A Cambridge UK-New York medical technology collaboration is promising to bring new hope to millions of patients across a raft of therapy areas.

IXICO plc, which has a strong portfolio in brain health and many other disease areas, has joined forces with Nasdaq quoted VirtualScopics, Inc for an unprecedented international research play.

The partners say that the proposed alliance will provide the clinical trials industry with global operational capabilities and a full range of therapeutic area and modality expertise.

This is expected to enhance the ability of both companies to deliver world-class services to pharmaceutical, biotech and academic customers and collaborators around the globe.

Derek Hill, CEO of IXICO said: “This alliance brings together two highly complementary organisations, each with a strong track record of supplying imaging services and technologies to pharmaceutical companies globally.

“By combining our resources with those of VirtualScopics, we can enhance our ability to deliver on the largest trials world-wide, across a more diverse range of therapeutic areas.”

Eric Converse, CEO of VirtualScopics added: “The proposed alliance would enable us to access IXICO’s focus on neurology, European location, and complementary technologies, and we believe, allow us to provide more comprehensive and scalable capabilities to our customers.”


Add new comment

Newsletter Subscription

Stay informed of the latest news and features